Author
Muthiah N. Inbasekaran
Bio: Muthiah N. Inbasekaran is an academic researcher from Dow Chemical Company. The author has contributed to research in topics: Ether & Fluorene. The author has an hindex of 11, co-authored 30 publications receiving 382 citations.
Topics: Ether, Fluorene, Alkyl, Propargyl, Nucleophilic substitution
Papers
More filters
•
24 Jun 1987TL;DR: A group of functionalized polyamine chelants that form complexes with radioactive rhodium is described in this article, which can be attached to an antibody or antibody fragment and used for therapeutic or diagnostic purposes.
Abstract: A group of functionalized polyamine chelants that form complexes with radioactive rhodium are disclosed. The rhodium complexes can be attached to an antibody or antibody fragment and used for therapeutic or diagnostic purposes.
83 citations
•
15 Mar 1993TL;DR: In this paper, a group of functionalized polyamine chelants that form complexes with rhodium are disclosed. The rhodIUM complexes can be attached to an antibody or antibody fragment and used for therapeutic or diagnostic purposes.
Abstract: A group of functionalized polyamine chelants that form complexes with rhodium are disclosed. The rhodium complexes can be attached to an antibody or antibody fragment and used for therapeutic or diagnostic purposes.
40 citations
•
09 Feb 1998TL;DR: In this article, a "cardo" diphenylene group was added to a dinucleophilic monomer with at least one dtglycidyl ether of a cardo bisphenol, such as bis(hydroxyphenyl)fluorene, phenolphthalein, or phenolphthalimidine.
Abstract: Hydroxy-functional polyethers having a "cardo" diphenylene group in their backbones are prepared by contacting at least one dinucleophilic monomer with at least one dtglycidyl ether of a cardo bisphenol, such as bis(hydroxyphenyl)fluorene, phenolphthalein, or phenolphthalimidine or a substituted cardo bisphenol, such as a substituted bis(hydroxyphenyl)fluorene, a substituted phenolphthalein or a substituted phenolphthalimidine, under conditions sufficient to cause the nucleophillo moieties of the dinucleophilic monomer to react with epoxy moieties to form a polymer backbone containing pendant hydroxy moieties and ether, imino, amino, sulfonamido or ester linkages. These polyethers possess a combination of high barrier to oxygen transmission (i.e., oxygen transmission rate less than 10.0 cm 3 -mil/100 in 2 -atm-day to oxygen) and high heat resistance (i.e., Tg above 120° C.). These polyethers are suitable for use in the manufacture of retort-sterilizable packaging materials exhibiting high barrier to oxygen.
35 citations
•
10 Apr 1992TL;DR: In this article, a nonlinear optical materials consisting of aminoaryl hydrazones and polymeric compositions containing recurring covalently bonded moieties derived from the aminoaryl hyrazones of the present invention was described.
Abstract: The present invention relates to nonlinear optical materials comprising aminoaryl hydrazones and to nonlinear optical polymeric compositions containing recurring covalently bonded moieties derived from the aminoaryl hydrazones of the invention. The polymeric compositions of the present invention have high glass transition temperatures and exhibit stable nonlinear optical activity at high temperatures over a period of time.
25 citations
•
20 Jun 1988
TL;DR: In this article, a group of functionalized polyamine chelants that form complexes with rhodium are disclosed. The rhodIUM complexes can be attached to an antibody or antibody fragment and used for therapeutic or diagnostic purposes.
Abstract: A group of functionalized polyamine chelants that form complexes with rhodium are disclosed. The rhodium complexes can be attached to an antibody or antibody fragment and used for therapeutic or diagnostic purposes.
21 citations
Cited by
More filters
•
29 Oct 2007TL;DR: The present invention encompasses albumin fusion proteins as discussed by the authors, as well as vectors containing these nucleic acids, host cells transformed with the nucleic acid vectors, and methods of making the fusion proteins of the invention.
Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
998 citations
•
12 Mar 2010
TL;DR: Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided in this article, including a method of forming the coatings, which can be used for the delivery of an active ingredient or a combination of active ingredients.
Abstract: Coatings for implantable devices or endoluminal prosthesis, such as stents, are provided, including a method of forming the coatings. The coatings can be used for the delivery of an active ingredient or a combination of active ingredients.
539 citations
•
26 Jul 1996TL;DR: In this article, the 2,7-substituted-9-substantituted fluorenes and polymers are substituted at the 2-and 7-positions with aryl moieties which are capable of cross-linking or chain extension or a trialkyl-siloxy moiety.
Abstract: The invention relates to 2,7-substituted-9-substituted fluorenes and 9-substituted fluorene oligomers and polymers. The fluorenes, oligomers and polymers are substituted at the 9-position with two hydrocarbyl moieties which may optionally contain one or more of sulfur, nitrogen, oxygen, phosphorous or silicon heteroatoms; a C5-20 ring structure formed with the 9-carbon on the fluorene ring or a C4-20 ring structure formed with the 9-carbon containing one or more heteroatoms of sulfur, nitrogen or oxygen; or a hydrocarbylidene moiety. In one embodiment, the fluorenes are substituted at the 2- and 7-positions with aryl moieties which may further be substituted with moieties which are capable of cross-linking or chain extension or a trialkylsiloxy moiety. The fluorene polymers and oligomers may be substituted at the 2- and 7'-positions. The monomer units of the fluorene oligomers and polymers are bound to one another at the 2- and 7'-positions. The 2,7'-aryl-9-substituted fluorene oligomers and polymers may be further reacted with one another to form higher molecular weight polymers by causing the optional moieties on the terminal 2,7'-aryl moieties, which are capable of cross-linking or chain extension, to undergo chain extension or cross-linking. Also disclosed are processes for preparing the disclosed compounds.
387 citations
•
12 Apr 2001
TL;DR: A stent of variable surface area as determined by stent struts can be cut with struts of variable thickness to provide the variable stent surface area as mentioned in this paper, and a patterned distribution of therapeutic agent can be provided throughout the stent.
Abstract: A stent of variable surface area as determined by stent struts. The stent can have a variable surface area per unit length which accommodates a therapeutic agent. A patterned distribution of therapeutic agent can be provided throughout the stent. The stent can have an increased level of therapeutic agent near an end of the stent. A decreased level of therapeutic agent can be provided near an end of one embodiment of a stent. Indentations can be provided at the surface of the stent with therapeutic agent disposed therein. The stent can be cut with struts of variable thickness to provide the variable stent surface area.
252 citations
•
07 Apr 2003
238 citations